CHIEF EXECUTIVE OFFICER
Rob Rayl, MBA, is an industry-leading healthcare executive with more than two decades of experience driving multi-million-dollar revenue growth in highly visible commercial roles. Rob is globally experienced in consulting, pharmaceuticals, diagnostics, biotechnology, diagnostics, and medical devices. He is widely recognized for building customer-centric cultures and delivering award-winning revenue growth throughout his career.
Rob has worked for market leading companies focused on oncology, diagnostics, wound care, and pressure injury prevention and treatment. While serving as President, US for Mölnlycke, Rob played an instrumental role in doubling revenues by differentiating the wound care portfolio with clinical evidence and health economics data.
Prior to joining Stage Analytics, he was Principal at R2 Medical Solutions. R2 Medical Solutions prepared go to market commercial strategies for pharmaceutical and medical device companies looking to enter the US market. While serving as Principal of R2 Medical Solutions, Rob was a board member at debra of America, served as an industry advisor to the National Pressure Injury Advisory Panel (NPIAP), and was on the advisory board at Monument Analytics where he worked closely with Dr. Alexander and Dr. Padula. Rob joined Stage Analytics as CEO in 2022.
Rob earned his Executive MBA in Leadership from the University of Georgia, Terry College of Business, a BS in Marketing Management from Valparaiso University (IN), and a Certificate in Leadership from the University of Virginia Darden School of Business. He sits on the Board and serves as Chief Development Officer of Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA of America), the only U.S. nonprofit providing all-inclusive support to the EB Community.